Instrument Inactif

Autres langues Tobira Therapeutics Inc

Actions

US88883P1012

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

2016

TOBIRA fait gagner plus de 40 000 euros à un investisseur !

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	20/10/16
Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	03/10/16
TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	21/09/16
Tobira Therapeutics : Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH	20/09/16
Tobira Therapeutics : Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin	12/09/16
Tobira Therapeutics : Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering Committee	07/09/16
Tobira Therapeutics : to Participate in Two Conferences in September	01/09/16
Tobira Therapeutics : Reports Second Quarter 2016 Financial and Business Results	09/08/16
Tobira Therapeutics : to Present at the 36th Annual Canaccord Genuity Growth Conference	02/08/16
Tobira Therapeutics Announces Date of 2016 Second Quarter Financial Results and CENTAUR Study Update Conference Call	01/08/16
Tobira Therapeutics : Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year	25/07/16
Tobira Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss CENTAUR Phase 2b Trial Results	25/07/16
Tobira Therapeutics : Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH	27/06/16
Tobira Therapeutics : Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH	27/06/16
Tobira Therapeutics : Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology	16/06/16
Tobira Therapeutics : Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology	16/06/16
Tobira Therapeutics Announces Date of 2016 First Quarter Financial Results and Conference Call	02/05/16
Tobira Therapeutics Announces Date of 2015 Fourth Quarter Financial Results and Conference Call	22/02/16
Tobira Therapeutics : to Present at the Bank of America Merrill Lynch 2015 Health Care Conference	14/05/15
Tobira Therapeutics : Completes Financing and Merger with Regado Biosciences	14/05/15

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Tobira Therapeutics Inc

Actions

US88883P1012

Autres langues

Filtres